New hope for advanced Hodgkin's lymphoma patients in china trial
NCT ID NCT04067037
Summary
This study is testing whether adding a new immunotherapy drug called camrelizumab to standard chemotherapy (AVD) works better for people with advanced Hodgkin's lymphoma who haven't had treatment before. The trial will enroll 60 patients to see if this combination helps more people achieve complete remission and is safe. Researchers hope this approach could provide better disease control for patients who currently face relapse risks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLASSICAL HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
An Yang Tumor Hospital
Anyang, Henan, 455000, China
-
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university
Zhengzhou, Henan, China
-
The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology
Luoyang, Henan, 471003, China
Conditions
Explore the condition pages connected to this study.